000285693 001__ 285693
000285693 005__ 20240229155116.0
000285693 0247_ $$2doi$$a10.21873/anticanres.16761
000285693 0247_ $$2pmid$$apmid:38030166
000285693 0247_ $$2ISSN$$a0250-7005
000285693 0247_ $$2ISSN$$a1791-7530
000285693 037__ $$aDKFZ-2023-02508
000285693 041__ $$aEnglish
000285693 082__ $$a610
000285693 1001_ $$0P:(DE-He78)0d76712a960555ea778f5b7f35334414$$aZhang, Xin-Wen$$b0$$eFirst author$$udkfz
000285693 245__ $$aAnalysis of an Unselected Patient Cohort With Advanced Colorectal Carcinoma from a Maximum Care Center.
000285693 260__ $$aAttiki$$b[Verlag nicht ermittelbar]$$c2023
000285693 3367_ $$2DRIVER$$aarticle
000285693 3367_ $$2DataCite$$aOutput Types/Journal article
000285693 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1701416233_30225
000285693 3367_ $$2BibTeX$$aARTICLE
000285693 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285693 3367_ $$00$$2EndNote$$aJournal Article
000285693 500__ $$a#EA:D240#LA:D240#
000285693 520__ $$aSystemic treatment for metastatic colorectal cancer (CRC) includes chemotherapy in combination with a targeted antibody. Novel targeted therapies and immunotherapies are introduced for specific molecular subgroups. Prognostic relevant determinants are still under investigation.Systemic therapies of an unselected patient cohort with metastatic CRC were retrospectively analyzed. Treatment outcome was evaluated according to time-to-next-treatment (TTNT) and frequency of conversion surgery and compared between subgroups stratified by primary tumor side, molecular profile, sex and age, and metastases sites.More than 50% of patients with locally advanced or metastatic CRC underwent secondary resection after first-line systemic therapy. Rectum carcinoma had the best prognosis under anti-EGFR-antibody treatment. Female patients had a worse prognosis than male patients in late disease stage. Young patients demonstrated poor response to systemic therapy, but a high rate of conversion surgeries. Conversely, elderly patients benefited from systemic therapy but underwent surgery less frequently. Liver and lung metastases had a worse prognosis than other metastases sites, whereas lung metastases were more likely to be resected than liver metastases in early disease stage.Patient age, sex, primary tumor localization, and metastatic sites are prognostic factors that could guide future treatment decisions for the therapy of metastatic CRC.
000285693 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000285693 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000285693 650_7 $$2Other$$aColorectal cancer
000285693 650_7 $$2Other$$achemotherapy
000285693 650_7 $$2Other$$acolorectal liver metastases
000285693 650_7 $$2Other$$ametastases
000285693 650_7 $$2Other$$asecondary surgery
000285693 650_7 $$2Other$$atime-to-next-treatment
000285693 650_7 $$2Other$$atumor sidedness
000285693 7001_ $$aMohr, Jutta$$b1
000285693 7001_ $$0P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aHalama, Niels$$b2$$eLast author$$udkfz
000285693 7001_ $$aKoschny, Ronald$$b3
000285693 773__ $$0PERI:(DE-600)2145376-7$$a10.21873/anticanres.16761$$gVol. 43, no. 12, p. 5589 - 5596$$n12$$p5589 - 5596$$tAnticancer research$$v43$$x0250-7005$$y2023
000285693 909CO $$ooai:inrepo02.dkfz.de:285693$$pVDB
000285693 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0d76712a960555ea778f5b7f35334414$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000285693 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000285693 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000285693 9141_ $$y2023
000285693 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANTICANCER RES : 2022$$d2023-10-25
000285693 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000285693 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000285693 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000285693 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000285693 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000285693 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000285693 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-25
000285693 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-25
000285693 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000285693 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000285693 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-25
000285693 9202_ $$0I:(DE-He78)D240-20160331$$kD240$$lTranslationale Immuntherapie$$x0
000285693 9201_ $$0I:(DE-He78)D240-20160331$$kD240$$lTranslationale Immuntherapie$$x0
000285693 9200_ $$0I:(DE-He78)D240-20160331$$kD240$$lTranslationale Immuntherapie$$x0
000285693 980__ $$ajournal
000285693 980__ $$aVDB
000285693 980__ $$aI:(DE-He78)D240-20160331
000285693 980__ $$aUNRESTRICTED